國家衛生研究院 NHRI:Item 3990099045/13507
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 857848      Online Users : 840
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/13507


    Title: Outcomes of second-line oral antidiabetic drugs in persons with young-onset type 2 diabetes
    Authors: Yen, FS;Wei, CC;Liu, JS;Hsu, CC;Hwu, CM
    Contributors: Institute of Population Health Sciences
    Abstract: AIM: People with young-onset diabetes (YOD) exhibit a higher risk of morbidity and mortality than those with late-onset diabetes. Few studies have explored the preferred management of diabetes in such patients. We compared the risks of hospitalization and mortality among people with YOD to whom second-line oral antidiabetic drugs (OADs) were administered. METHODS: 7257 people taking second-line OADs after initial metformin therapy were enrolled during 2009-2014. Using add-on sulfonylureas (SUs) as a reference, the multivariable Cox regression model was used to compare the hospitalization and mortality risks among 5 categories of second-line OADs: alpha-glucosidase inhibitors, meglitinide, dipeptidyl peptidase-4 (DPP-4) inhibitors, SUs, and thiazolidinediones. RESULTS: After baseline characteristics, comorbidities, duration of diabetes, and drug use were controlled, the adjusted hazard ratios and 95% confidence interval for all-cause, cardiovascular, and non-infection hospitalization and all-cause mortality for metformin plus DPP-4 inhibitors were 0.62 (0.52-0.73), 0.49 (0.29-0.85), 0.64 (0.54-0.76), and 0.50 (0.27-0.92), respectively, when compared with the data for metformin plus SUs. CONCLUSIONS: Among people with YOD, taking add-on DPP-4 inhibitors was associated with lower risks of all-cause hospitalization and mortality than taking add-on SUs. DPP-4 inhibitors thus seem to be a suitable second-line OAD for such patients.
    Date: 2021-07
    Relation: Diabetes Research and Clinical Practice. 2021 Jul;177:Article number 108928.
    Link to: http://dx.doi.org/10.1016/j.diabres.2021.108928
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0168-8227&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000680513200006
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85109531337
    Appears in Collections:[Chih-Cheng Hsu] Periodical Articles

    Files in This Item:

    File SizeFormat
    PUB34171441.pdf807KbAdobe PDF196View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback